156 related articles for article (PubMed ID: 9193832)
1. Comparison of F-18 FDG to I-123 and I-131 scans in thyroid carcinoma.
Bakheet SM; Powe JE; Hammami MM; Ahmed M
Clin Nucl Med; 1997 Jun; 22(6):438-9. PubMed ID: 9193832
[No Abstract] [Full Text] [Related]
2. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide.
Scott GC; Meier DA; Dickinson CZ
J Nucl Med; 1995 Oct; 36(10):1843-5. PubMed ID: 7562053
[TBL] [Abstract][Full Text] [Related]
3. Early changes in fluorine-18-FDG uptake during radiotherapy.
Hautzel H; Müller-Gärtner HW
J Nucl Med; 1997 Sep; 38(9):1384-6. PubMed ID: 9293793
[TBL] [Abstract][Full Text] [Related]
4. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
Wu YJ; Wu HS; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(3C):2973-6. PubMed ID: 12926147
[TBL] [Abstract][Full Text] [Related]
5. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
Shiga T; Tsukamoto E; Nakada K; Morita K; Kato T; Mabuchi M; Yoshinaga K; Katoh C; Kuge Y; Tamaki N
J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
[TBL] [Abstract][Full Text] [Related]
6. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
[TBL] [Abstract][Full Text] [Related]
7. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
8. [PET-FDG in thyroid cancer with high thyroglobulin levels and negative 131-I scan. A case report].
Ortega F; Maldonado A; Marañes P; Montz R; Pérez-Castejón MJ; Melgarejo M; Ruiz JA; Carreras JL
Rev Esp Med Nucl; 1999; 18(1):50-4. PubMed ID: 10074219
[TBL] [Abstract][Full Text] [Related]
9. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A
Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography of thyroid masses.
Adler LP; Bloom AD
Thyroid; 1993; 3(3):195-200. PubMed ID: 8257858
[TBL] [Abstract][Full Text] [Related]
11. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
[TBL] [Abstract][Full Text] [Related]
12. (18)F-FDG PET discovered an elusive cervical inflammatory pseudotumor associated with a papillary thyroid cancer.
Modesto J; Gardeazabal I; Santos AM; Galofré JC
Endocrinol Nutr; 2014; 61(6):338-40. PubMed ID: 24721020
[No Abstract] [Full Text] [Related]
13. [18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I].
Feine U; Lietzenmayer R; Hanke JP; Wöhrle H; Müller-Schauenburg W
Nuklearmedizin; 1995 Aug; 34(4):127-34. PubMed ID: 7675641
[TBL] [Abstract][Full Text] [Related]
14. An intrapericardial ectopic thyroid mimicking metastasis in a patient with papillary thyroid cancer: Localization, differential diagnosis by
Park SH; Seo M; Park TY; Nam-Goong S
Hell J Nucl Med; 2016; 19(3):272-274. PubMed ID: 27824968
[TBL] [Abstract][Full Text] [Related]
15. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
16. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
17. [Pathological thyroid uptake in Cushing's syndrome: an unexpected finding].
Civantos Modino S; Montaño Martínez J; Pavón de Paz I; Guijarro de Armas G; Monereo Megías S
Endocrinol Nutr; 2011; 58(6):315-7. PubMed ID: 21497569
[No Abstract] [Full Text] [Related]
18. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
[TBL] [Abstract][Full Text] [Related]
19. Whole-body scintigraphy with 99Tcm-MIBI, 18F-FDG and 131I in patients with metastatic thyroid carcinoma.
Fridrich L; Messa C; Landoni C; Lucignani G; Moncayo R; Kendler D; Riccabona G; Fazio F
Nucl Med Commun; 1997 Jan; 18(1):3-9. PubMed ID: 9061694
[TBL] [Abstract][Full Text] [Related]
20. Normal uptake of F-18 FDG in the sublingual gland.
Bogsrud TV; Karantanis D; Lowe VJ
Clin Nucl Med; 2006 Jan; 31(1):50. PubMed ID: 16374130
[No Abstract] [Full Text] [Related]
[Next] [New Search]
